Journavx for Pain Management: Toward Affordability and Access
In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the NaV1.8 sodium channel for moderate-to-severe acute ...
Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Har...
“The Cost of Defunding Scientific Research,” written by Atul Gawande, argues that the Trump Administration’s threatened federal funding cuts to Harvard and affiliated hospitals would have catastrophic effects on American scientific research, patient care, and public health. The article details th...
FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment
The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin as a neoadjuvant therapy, followed by adjuvant durvalumab after radical cystectomy for adults with muscle-invasive bladder cancer (MIBC). This marks the first perioperative immunotherapy bladder cancer regimen...
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
The article reviews MARIE, a qualitative multiple-criteria value-based drug pricing (VBP) framework designed for the Japanese drug pricing system to address price adjustments for drugs with updated clinical status. By applying MARIE to 32 drugs, a recently published study found that changes in th...
Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression
This review examines a systematic study identifying 17 modifiable risk factors linked to stroke, dementia, and late-life
Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Ch...
The executive order "Lowering Drug Prices by Once Again Putting Americans First" establishes a policy agenda focused on drug price regulation to reduce prescription drug costs in the U.S. This initiative revisits and expands prior efforts, such as promoting generics and enhancing transparency. It...
